Tripos International, a leading provider of drug discovery informatics products and services, today announced the development of PantheonTM, a new, flexible and powerful software platform created to address the CADD and cheminformatics needs of the casual modeler and medicinal chemist.
Pantheon provides an affordable, extendable cheminformatics solution for a broad range of discovery scientists allowing them to significantly reduce time involved in the discovery process, and to improve critical decision steps, by organizing, analyzing and visualizing chemical and biological data in a single program. Pantheon will launch a public software beta in the fourth quarter of 2008 and is targeted for commercial release in the first quarter of 2009.
By itself, Pantheon incorporates a robust set of basic cheminformatics and modeling tools and streamlined workflows that facilitate simple experiments and the sharing of results between and among users, allowing them to use best-of-breed techniques employed in a single application. It will also serve as an underlying engine for an additional range of significant molecular discovery solutions anticipated from Tripos and provided by third party vendors in the future. Pantheon will serve to satisfy the exacting scientific requirements and the open IT infrastructure standards of today's dynamic development environment.
Tripos Chief Technology Officer, Gregory Smith, Ph.D., made the announcement, saying, "With Pantheon, discovery organizations have an open, extendable platform for developing rich chemistry and life science workflows. This is an open platform for drug design and informatics based on the Eclipse platform which reduces the costs associated with platform development. Pantheon is easily extendable by in-house discovery IT teams, as well as external suppliers, meaning that organizations can have an ideal software environment to deliver workflow-based data analysis and modeling, across the spectrum of discovery scientists."
According to Jim Hopkins, Tripos' CEO, "Pantheon enables discovery organizations to increase research efficiencies by providing a single, integrated platform on which users create virtual, tailored experiments. They can then share that knowledge and rapidly make smart decisions about the results and the next steps. Discovery scientists have really never had a consistent, manageable method of simplifying the process, reducing application fatigue and ensuring that data is not lost during the transfer between dissimilar applications. Pantheon is easily adopted by a single scientist or across the entire enterprise."
For more information about Pantheon, contact Tripos by email at contact_us@tripos.com or by phone in the US at 1-314-647-1099 or 1-800-323-2960, in Germany at +49 89 45 10 300, or in France at +33 1 69 59 29 43.
About the New Tripos International
Tripos International is a global leader in innovative scientific solutions that enable life science researchers to improve the efficiency of their molecular discovery efforts. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical and food design industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds that have the potential to become new products in the drug, food, flavoring and fragrance markets. Headquartered in St. Louis, Missouri, Tripos International serves more than 1,000 customers spanning over 46 countries. Tripos is wholly owned by Vector Capital, a San Francisco-based private equity boutique specializing in buyouts, spinouts and recapitalizations of established technology businesses.